4-(S)-[1-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine | 578706-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(S)-[1-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine
• 英文别名: 4-(S)-[1-[(3,5-Bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin4-yl]-piperazine；(2R,4S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-piperazin-1-ylpiperidine-1-carboxamide
• CAS: 578706-51-1
• 化学式: C₂₇H₃₁F₇N₄O
• 分子量: 560.558
• InChiKey: JYUBSEKBLPTPRS-LADGPHEKSA-N

物化性质

• 沸点：
  566.7±50.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  39
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  38.8
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  4-(S)-[1-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine 、 三光气 、 甲胺 在 三氟乙酸 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 20.0h， 生成 4-(S)-[1-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine-1-carboxylic acid methylamide
  参考文献：
  名称：

  Chemical compounds

  摘要：

  公式（1）中，R代表卤原子或C1-4烷基；R1代表C1-4烷基；R2代表氢或C1-4烷基；R3代表氢或C1-4烷基；R4代表三氟甲基基团；R5代表氢、C1-4烷基或C(0)R6；R6代表C1-4烷基、C3-7环烷基、NH(C1-4烷基)或N(C1-4烷基)2；m为零或1至3的整数；n为1至3的整数及其药学上可接受的盐和溶剂化合物；以及它们的制备过程和在通过tachykinins介导的疾病治疗中的用途。

  公开号：

  US20040014770A1
• 作为产物：
  描述：

  4-(S)-[1-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 4-(S)-[1-[(3,5-bis-trifluoromethyl-benzyl)-methyl-carbamoyl]-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidin-4-yl]-piperazine
  参考文献：
  名称：

  Chemical compounds

  摘要：

  公式（1）中，R代表卤原子或C1-4烷基；R1代表C1-4烷基；R2代表氢或C1-4烷基；R3代表氢或C1-4烷基；R4代表三氟甲基基团；R5代表氢、C1-4烷基或C(0)R6；R6代表C1-4烷基、C3-7环烷基、NH(C1-4烷基)或N(C1-4烷基)2；m为零或1至3的整数；n为1至3的整数及其药学上可接受的盐和溶剂化合物；以及它们的制备过程和在通过tachykinins介导的疾病治疗中的用途。

  公开号：

  US20040014770A1

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2002032867A1

  公开（公告）日：2002-04-25

  Formula (1) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen, or a C1-4 alkyl group; R4 represents a trifluorometyl group; R5 represents hydrogen, a C1-4 alkyl group or C(0)R6; R6 represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from1 to 3 and pharmaceutically acceptable salts and solvates thereof; to processes for their preparation and their use in the treatment of conditions mediated bytachykinins.

  公式（1），其中R代表卤素原子或C1-4烷基；R1代表C1-4烷基；R2代表氢或C1-4烷基；R3代表氢或C1-4烷基；R4代表三氟甲基基团；R5代表氢，C1-4烷基或C（0）R6；R6代表C1-4烷基，C3-7环烷基，NH（C1-4烷基）或N（C1-4烷基）2；m为零或1至3的整数；n为1至3的整数，以及其药学上可接受的盐和溶剂合物；其制备过程及其在治疗由速激肽介导的疾病中的应用。
• Piperidine derivatives and their use as antagonists of tachykinins
  申请人：Alvaro Giuseppe

  公开号：US20050096313A1

  公开（公告）日：2005-05-05

  The present invention relates to piperidine derivatives of formula (I): wherein R represents halogen or C 1-4 alkyl; R 1 represents hydrogen or C 1-4 alkyl; R 2 represents hydrogen, C 1-4 alkyl; R 3 represents hydrogen, C 1-4 alkyl; R 4 represents trifluoromethyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy or halogen; R 5 represents hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C(O)R 6 or S(O) 2 R 6 ; R 6 represents C 1-4 alkyl or C 3-7 cycloalkyl; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p is an integer from 1 to 2; X and Y are independently C(O) or CH 2 ; provided that i) X and Y are not both C(O) and ii) when X and Y are both CH 2 and p is 1, R 5 is not hydrogen, C 1-4 alkyl or C(O)R 6 ; and pharmaceutically acceptable salts and solvates thereof, the process for their preparation and their use in the treatment of conditions mediated by tachykinins.

  本发明涉及式（I）的哌啶衍生物：其中R代表卤素或C1-4烷基；R1代表氢或C1-4烷基；R2代表氢，C1-4烷基；R3代表氢，C1-4烷基；R4代表三氟甲基，C1-4烷基，C1-4烷氧基，三氟甲氧基或卤素；R5代表氢，C1-4烷基，C3-7环烷基，C（O）R6或S（O）2R6；R6代表C1-4烷基或C3-7环烷基；m为零或1至3的整数；n为1至3的整数；p为1至2的整数；X和Y分别为C（O）或CH2；前提是i）X和Y不都是C（O）；以及ii）当X和Y都是 且p为1时，R5不是氢，C1-4烷基或C（O）R6；以及其药学上可接受的盐和溶剂合物，其制备过程及其在治疗缓解性肽介导的疾病中的用途。
• PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS
  申请人：Alvaro Giuseppe

  公开号：US20090318530A1

  公开（公告）日：2009-12-24

  The present invention relates to pharmaceutical compositions comprising an NK1 receptor antagonist and a sodium channel blocker compound of formula (I) wherein R 1 and R 2 are independently hydrogen, C 1-6 alkyl or C 3-6 cycloalkylC 1-6 alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, may form an unsubstituted 3-, 4-, 5- or 6-membered saturated ring; q is 1 or 2; R 3 and R 4 are hydrogen; or when q is 1, R 3 and R 4 , together with the interconnecting atoms, may form a cyclopropane ring; X is carbon or nitrogen; n is 0, 1 or 2, wherein when present each R 5 is independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; and either R 6 or R 7 is —O—R 8 or —OCH 2 R 8 , wherein the other R 6 or R 7 is hydrogen or R 5 ; and wherein R 8 is either a phenyl ring or a 5- or 6-membered aromatic heterocyclic ring (independently containing one or more nitrogen, sulphur or oxygen atoms) wherein either the phenyl ring or the heterocyclic ring is optionally substituted by one or more groups independently selected from the list consisting of C 1-3 alkyl, halogen, cyano, haloC 1-3 alkyl, hydroxy, C 1-3 alkoxy and C 1-3 haloalkoxy; or a pharmaceutically acceptable salt or solvate thereof; as a combined preparation for simultaneous or sequential administration, and to the use of such compositions in the treatment of certain disorders, including epilepsy and mood disorders.

  本发明涉及一种药物组合物，包括NK1受体拮抗剂和式(I)的钠通道阻滞剂化合物，其中R1和R2独立地为氢、C1-6烷基或C3-6环烷基C1-6烷基；或者R1和R2连同它们所连接的氮原子可以形成未取代的3、4、5或6成员饱和环；q为1或2；R3和R4为氢；或者当q为1时，R3和R4连同相互连接的原子可以形成环丙烷环；X为碳或氮；n为0、1或2，其中当存在时，每个R5独立地从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中选择；且R6或R7为—O—R8或—OCH2R8，另一个R6或R7为氢或R5；其中R8为苯环或5-或6-成员芳香杂环环（独立地包含一个或多个氮、硫或氧原子），其中苯环或芳香杂环环中的任一环都可以选择一个或多个独立的基团进行取代，所述基团从C1-3烷基、卤素、氰基、卤代C1-3烷基、羟基、C1-3烷氧基和C1-3卤代烷氧基的列表中独立选择；或其药学上可接受的盐或溶剂；作为同时或顺序给药的联合制剂，并且将这种组合物用于治疗某些疾病，包括癫痫和情感障碍。
• Piperazinyl piperidine tachykinin antagonists
  申请人：SmithKline Beecham Corporation

  公开号：US07294630B2

  公开（公告）日：2007-11-13

  The present invention provides compounds of formula (I): wherein each R independently represents a halogen atom or a C1-4 alkyl group; R1 represents a C1-4 alkyl group; R2 represents hydrogen or a C1-4 alkyl group; R3 represents hydrogen or C1-4 alkyl group; R4 represents a trifluoromethyl group; R5 represents hydrogen, a C1-4 alkyl group or C(O)R6; R6 represents C1-4 alkyl, C3-7 cycloalkyl, NH(C1-4 alkyl) or N(C1-4alkyl)2; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; or a pharmaceutically acceptable salt or solvate thereof; compositions containing the same, processes for their preparation and methods for their use in the treatment of conditions mediated by tachykinins.

  本发明提供了式（I）的化合物： 其中每个R独立地表示卤素原子或C1-4烷基基团；R1表示C1-4烷基基团；R2表示氢或C1-4烷基基团；R3表示氢或C1-4烷基基团；R4表示三氟甲基基团；R5表示氢，C1-4烷基基团或C（O）R6；R6表示C1-4烷基，C3-7环烷基，NH（C1-4烷基）或N（C1-4烷基）2；m为零或1至3的整数；n为1至3的整数；或其药学上可接受的盐或溶剂；包含其的组合物、其制备的方法以及用于治疗由快速肽介导的疾病的方法。
• Chemical Compounds
  申请人：Alvaro Giuseppe

  公开号：US20080021041A1

  公开（公告）日：2008-01-24

  The present invention provides a method for the treatment of emesis in a mammal being treated with an opiod analgesic

  本发明提供了一种用于治疗哺乳动物在使用阿片类镇痛药物时恶心的方法。